Brind.

Comparison of Curaleaf and Profound Medical Stock Metrics

1 report, 1 independent Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Curaleaf and Profound Medical are both classified as small-cap healthcare companies. A comparison of the two businesses showed that Profound Medical has higher earnings than Curaleaf, though it reports lower gross revenue. Curaleaf trades at a lower price-to-earnings ratio than Profound Medical, while Curaleaf also exhibits higher volatility, with a beta of 1.62 compared to Profound Medical's beta of 0.79.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The comparison provides insight into the differing risk and valuation profiles of the two companies. Curaleaf's lower price-to-earnings ratio suggests it is currently more affordable, while Profound Medical's lower beta indicates a less volatile stock price relative to the S&P 500.

From themarketsdaily.com

Who's involved

  • CuraleafCanadian cannabis company subject to the comparison

Keep exploring

The entities involved

  • Curaleaf

    Canadian cannabis company

    Nothing else this week.

Coverage

Newest first; wire copies grouped